Literature DB >> 8443402

Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.

S R Milovanovic1, S Radulovic, A V Schally.   

Abstract

The binding characteristics of several cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH) developed in our laboratory were examined in membranes from human breast cancer and estrogen independent MXT mammary cancer. Specific binding of [125I]D-Trp6-LH-RH and the cytotoxic LH-RH analog [125I]T-98 ([D-Lys6]LH-RH coupled to glutaryl-2-(hydroxymethyl)anthraquinone) (HMAQG) was demonstrated in membrane preparations from human breast and MXT mammary tumor cells. Ligand binding of T-98 was specific, saturable, and dependent on temperature, time, and plasma membrane concentration. Analysis of the binding data showed that in human breast cancer, interaction of [125I]T-98 was consistent with the presence of two classes of LH-RH receptors, one class showing high affinity and low capacity, and the other class showing low affinity and high capacity binding. In membranes from MXT mammary cancer, T-98 bound to one class of saturable, specific, noncooperative binding sites with high affinity and low capacity. The rates of association and dissociation for [125I]T-98 were calculated to be 4.757 x 10(8) M-1 min-1 and 0.016 min-1 (t1/2 = 38.7) in membranes from MXT mammary cancer. In human breast cancer, association rate constants (K1a and K1b) were 2.3 x 10(6) M-1 min-1 for binding to high affinity and 1.8 x 10(4) M-1 min-1 for binding to low affinity binding sites. Dissociation rate constants were K-1a = 0.0801 min-1 (t1/2a = 63.4 min) and K-1b = 0.0467 min-1 (t1/2b = 23.5 min), respectively. [125I]T-98 was not displaced by either unlabeled somatostatin or epidermal growth factor, but was displaced completely by unlabeled T-98 or [D-Trp6]LH-RH. The analysis of displacement curves of [D-Trp6]LH-RH by cytotoxic agonists and antagonists of LH-RH synthesized in our laboratory showed that T-121, AJ-11, T-120, T-133, and T-98 were the most potent in displacing [125I]D-Trp6-LH-RH from breast and MXT cancer membranes. Binding kinetics and analyses of displacement curves of [125I]D-Trp6-LH-RH and [125I]T-98 in membranes of human breast cancer and estrogen independent MXT mouse mammary cancer suggest that binding of the cytotoxic analog T-98 to the LH-RH receptor proceeds reversibly like that of its congeners without cytotoxic radicals. Our findings may provide a stimulus for further studies with LH-RH analogs carrying cytotoxic radicals.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 8443402     DOI: 10.1007/bf01961247

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

Review 1.  Endocrine treatment of breast cancer in women.

Authors:  R J Santen; A Manni; H Harvey; C Redmond
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

2.  Gonadotropin-releasing hormone binding to rat anterior pituitary membrane homogenates. Comparison of antagonists and agonists using radiolabeled antagonist and agonist.

Authors:  M H Perrin; Y Haas; J E Rivier; W W Vale
Journal:  Mol Pharmacol       Date:  1983-01       Impact factor: 4.436

3.  Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists.

Authors:  K A Eidne; C A Flanagan; N S Harris; R P Millar
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

4.  Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist.

Authors:  W R Miller; W N Scott; R Morris; H M Fraser; R M Sharpe
Journal:  Nature       Date:  1985 Jan 17-23       Impact factor: 49.962

5.  Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.

Authors:  M Fekete; J L Wittliff; A V Schally
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

6.  Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells.

Authors:  E Loumaye; K J Catt
Journal:  Science       Date:  1982-02-19       Impact factor: 47.728

8.  Receptor-binding properties of gonadotropin-releasing hormone derivatives. Prolonged receptor occupancy and cell-surface localization of a potent antagonist analog.

Authors:  E Loumaye; P C Wynn; D Coy; K J Catt
Journal:  J Biol Chem       Date:  1984-10-25       Impact factor: 5.157

9.  Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.

Authors:  Y Sharoni; E Bosin; A Miinster; J Levy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.

Authors:  T Janáky; A Juhász; S Bajusz; V Csernus; G Srkalovic; L Bokser; S Milovanovic; T W Redding; Z Rékási; A Nagy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

View more
  4 in total

1.  A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy.

Authors:  X Wang; L J Krebs; M Al-Nuri; H E Pudavar; S Ghosal; C Liebow; A A Nagy; A V Schally; P N Prasad
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts.

Authors:  B Vincze; I Pályi; D Daubner; A Kálnay; G Mezö; F Hudecz; M Szekerke; I Teplán; I Mezö
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.

Authors:  S R Milovanovic; E Monje; K Szepeshazi; S Radulovic; A Schally
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 4.  Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.

Authors:  Marta Venturelli; Giorgia Guaitoli; Claudia Omarini; Luca Moscetti
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-03-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.